Latest News

The problem is more with AMD stock than with AMD as a company.

Emerging growth opportunities in the AI ecosystem could send Nvidia stock higher by 2030.

Over $500 million in maturing securities are repricing toward 6%, structurally expanding margins without waiting for Fed moves.

Record margins let Interactive Brokers convert trading volume into shareholder cash, while AI tools and wealth management expansion target new growth vectors.

Artificial intelligence (AI) demand is fueling a boom for memory chips.

The memory-chip maker is severely undervalued relative to its outlook.

The company is growing fast, but it's expensive.

Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.

Bond investors are showing less confidence in this key growth driver for Nvidia.

CrowdStrike has delivered huge growth, but it comes at a cost.

Net interest margins are positioned for structural recovery as the interest rate environment turns and higher-yielding assets reprice.

The company's expertise in gene editing could lead to more breakthroughs.

ServiceNow has pulled further ahead over the past two years, but Workday's growth remains steady — here's what the diverging trajectories mean for your portfolio.

Azure's growth and Copilot's position in enterprise AI make Microsoft a smart AI play.

Is Citigroup the best big bank stock right now? You could make a case for it.

Apple and Nvidia have become the world's first $5 trillion stocks.

Deep contingency reserves and clean asset quality give the bank a cushion to weather economic shocks while pursuing growth.

Micron is starting to see memory deals extend beyond 2030.

Cost savings are accelerating ahead of schedule, creating operating leverage without major upfront investment.

Taiwan Semiconductor reported yet another impressive quarter the other day.

GTA VI arrives Nov. 19. Here's which video game stock looks like the best buy before launch.

It has been a volatile year for the biotech.

Larger issues loom at home for the Canada-based cannabis company.

Green Thumb's financial strength could outweigh Washington's regulatory delays.

Right now, the market is rewarding companies invested in the AI build-out. They may not be the ultimate winners.